| ID Source | ID |
|---|---|
| PubMed CID | 26436 |
| CHEMBL ID | 1886408 |
| CHEBI ID | 31598 |
| SCHEMBL ID | 3227634 |
| MeSH ID | M0139449 |
| Synonym |
|---|
| felbinac ethyl |
| lm-001 |
| ljc-10253 |
| daitac |
| ethyl (4-biphenylyl)acetate |
| acetic acid, (4-biphenylyl)-, ethyl ester |
| ethyl p-biphenylylacetate |
| 4-biphenylylacetic acid ethyl ester |
| brn 2052035 |
| 4-biphenylacetic acid, ethyl ester |
| felbinac ethyl ester |
| (1,1'-biphenyl)-4-acetic acid ethyl ester |
| NCGC00160454-01 |
| 14062-23-8 |
| D01841 |
| lm 001 |
| felbinac ethyl (jan) |
| FT-0652949 |
| ethyl 2-(4-phenylphenyl)acetate |
| AKOS001253929 |
| A807667 |
| 978zps989u , |
| felbinac ethyl [jan] |
| 3-09-00-03321 (beilstein handbook reference) |
| unii-978zps989u |
| cas-14062-23-8 |
| tox21_111824 |
| dtxsid3046160 , |
| dtxcid1026160 |
| felbinac ethyl ester [mi] |
| (1,1'-biphenyl)-4-acetic acid, ethyl ester |
| ethyl 4-biphenylylacetate |
| felbinac ethyl ester [who-dd] |
| diatec |
| ethyl (4'-biphenyl)acetate |
| NPPJLSILDPVHCM-UHFFFAOYSA-N |
| SCHEMBL3227634 |
| CHEMBL1886408 |
| SR-01000944969-1 |
| sr-01000944969 |
| CHEBI:31598 |
| ethyl 4-biphenylyl acetate |
| 4-biphenylacetic acid ethyl ester |
| felbinac-ethyl |
| ethyl 2-([1,1'-biphenyl]-4-yl)acetate |
| Q27271986 |
| biphenyl-4-ylacetic acid ethyl ester |
| CS-0361363 |
| ethyl2-([1,1'-biphenyl]-4-yl)acetate |
| mfcd01740348 |
| ethyl 2-{[1,1'-biphenyl]-4-yl}acetate |
| EN300-15134876 |
| bdbm442805 |
| Z53836330 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Among the three beta-CyDs, HP-beta-CyD was best at improving the rectal bioavailability of EBA in rats after single and multiple administrations of oleaginous suppositories (Witepsol H-5) containing the complexes." | ( Enhanced rectal absorption and reduced local irritation of the anti-inflammatory drug ethyl 4-biphenylylacetate in rats by complexation with water-soluble beta-cyclodextrin derivatives and formulation as oleaginous suppository. Arima, H; Irie, T; Kondo, T; Uekama, K, 1992) | 0.28 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| biphenyls | Benzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 32.1968 | 0.0072 | 15.7588 | 89.3584 | AID624030 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 8.3446 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 18.7207 | 0.0010 | 19.4141 | 70.9645 | AID743094; AID743140 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Replicase polyprotein 1ab | Betacoronavirus England 1 | IC50 (µMol) | 10.0000 | 0.0040 | 3.4388 | 9.5100 | AID1640022 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 (µMol) | 0.2000 | 0.0002 | 2.4585 | 9.9600 | AID1640021 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| double membrane vesicle viral factory outer membrane | Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 6 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.63) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||